Story
Ionis Pharmaceuticals Shares Plunge After Heart Drug Eplontersen Fails Phase 3 Trial
Summary
Ionis Pharmaceuticals (NASDAQ:IONS) stock fell over 20% after its cardiovascular drug eplontersen, developed with AstraZeneca, failed to meet its primary goals in a large-scale Phase 3 study. The setback significantly alters the drug's commercial outlook and benefits competitor Alnylam.
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) plummeted more than 20% in pre-market trading after the company and its partner AstraZeneca announced that a pivotal Phase 3 trial for their drug eplontersen failed to meet its primary endpoint. The result is a major setback for a treatment that was considered a cornerstone of Ionis's future growth.
Trial Fails to Meet Primary Endpoint
The CARDIO-TTRansform study evaluated the efficacy of eplontersen in 1,432 adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a progressive and fatal heart condition. According to the company's statement, the trial did not achieve its primary objective: a composite of reducing cardiovascular mortality and recurrent cardiovascular events by Week 140 compared to a placebo.
Ionis noted that in a prespecified subgroup, patients receiving eplontersen as a monotherapy showed a nominally significant benefit. However, this was not sufficient to make the overall trial successful. CEO Brett P. Monia stated the company was "disappointed that the study did not meet the primary endpoint," attributing the outcome in part to a "rapidly evolving treatment landscape" where patients are widely treated with stabilizer therapies.
AdCompetitive and Market Impact
The trial failure deals a significant blow to Ionis's commercial strategy, as a successful outcome was expected to expand eplontersen's market far beyond its current approval for a related nerve disorder. The news directly benefits competitors in the ATTR space, particularly Alnylam Pharmaceuticals (NASDAQ:ALNY), which markets the approved ATTR-CM therapy Amvuttra. The eplontersen setback removes a near-term competitive threat to Alnylam's growing franchise.
The sharp, company-specific sell-off reversed recent gains for Ionis stock, which had reached a 52-week high in the previous session. The news forces investors and analysts, who had been broadly bullish on the company's prospects, to reassess the near-term revenue potential of one of its key pipeline assets.